Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus apatinib for relapsed or refractory small cell lung cancer
ChiCTR2000031685Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and paclitaxel in small cell lung cancer (SCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Dec 2019; status: recruiting.
02
Drugs
Rivoceranibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000031685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031685.